“The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson’s disease with or without a GBA1 mutation. This is underscored by the promising biomarker and early clinical evidence from our ongoing Phase 1b study supporting the potential disease modifying properties of GT-02287 that we presented at AD/PD(TM) 2026 in Copenhagen this past March,” said Gene Mack, President and CEO of Gain Therapeutics (GANX).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics management to meet with Maxim
- Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
- Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
- Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
- Gain announces presentations on Phase 1b clinical study of GT-02287